Answers are grounded in this paper and cite their sources.
INTRODUCTION: Preeclampsia is a leading cause of maternal and perinatal morbidity and is increasingly understood as a disorder of maternal-fetal immune maladaptation, in which interleukin-6 (IL-6) occupies a central position. IL-6 is usually examined at a single disease stage, which obscures its role as a continuous mediator. CONTENT: This narrative review traces IL-6 across the preeclampsia continuum: signalling biology; the decidual immune niche; the regulatory T-cell/T-helper-17 and signal transducer and activator of transcription 3 axes; defective placentation; antiangiogenic endothelial injury; the clinical phenotype; postpartum inflammation; and remote cardiovascular disease. Evidence is labelled by provenance, the roles of IL-6 as biomarker, mediator and therapeutic target are distinguished, and aspirin, heparin and IL-6-directed therapies are appraised. SUMMARY: work; human data are associative and confounded by shared cardiometabolic risk; and the first large trial of IL-6 ligand inhibition lowered inflammation without reducing cardiovascular events. OUTLOOK: Longitudinal, signalling-specific measurement, explicit separation of marker from mediator and target, and safety-led evaluation in pregnancy are required before this axis can inform prevention or postpartum cardiovascular risk stratification.
No takes yet. Share an insight, caveat, or question.
Baroutis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: